Skip to main content

Correction: Reducing the harms of xylazine: clinical approaches, research deficits, and public health context

The Original Article was published on 30 September 2023

Correction : Harm Reduction Journal (2023) 20:1

In the original version of this article [1], the paragraph under the section “Drug War Failure” should read as follows:

Xylazine is unscheduled at the federal level, and to date is illegal only in Florida, where it was banned in 2018 [40]. Increased attention to xylazine and its harms has recently prompted a call for xylazine to be federally scheduled. However, we urge caution in such an approach. Scheduling xylazine would only control the licit supply, creating barriers to needed research on the health impacts, toxicology, and safety profile of the drug. Further, xylazine is used very commonly as a surgical anesthetic for animals used in pre-clinical research, including cancer research. Scheduling xylazine would disrupt these research areas and slow progress.

The original article has been corrected.


  1. Zagorski CM, et al. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20:141.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Claire M. Zagorski.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zagorski, C.M., Hosey, R.A., Moraff, C. et al. Correction: Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J 20, 170 (2023).

Download citation

  • Accepted:

  • Published:

  • DOI: